MOTS-c Research Overview

Discovery and Origin

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid peptide first characterized by Lee et al. in 2015. Its discovery was significant for a fundamental reason: MOTS-c is encoded not in the nuclear genome, as most signaling peptides are, but within mitochondrial DNA (mtDNA) — specifically the 12S rRNA gene. This makes it one of only a handful of known peptides of mitochondrial origin, a class now termed "mitochondria-derived peptides" or MDPs.

The identification of biologically active peptides encoded in mitochondrial rRNA genes was itself a paradigm-shifting finding. Ribosomes do not translate rRNA — or so it was believed. MOTS-c and a related peptide, Humanin (also mtDNA-encoded), have forced a reconsideration of mitochondrial genome biology: certain regions previously annotated as non-coding may encode short functional peptides with systemic endocrine effects.

16 Amino Acids · 2015 Year Characterized · 12S rRNA Gene Origin · AMPK Primary Effector Pathway

Mechanism of Action

MOTS-c's primary mechanistic action involves the folate cycle and one-carbon metabolism within cells. Under physiological conditions, MOTS-c is synthesized in mitochondria and released into the cytoplasm, where it inhibits the folate cycle enzyme AICAR transformylase. This inhibition results in accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is a potent physiological activator of AMPK (AMP-activated protein kinase).

AMPK is a master regulator of cellular energy homeostasis. Its activation by MOTS-c triggers a cascade of metabolic adaptations: enhanced glucose uptake in skeletal muscle (GLUT4 translocation), fatty acid oxidation, mitochondrial biogenesis, and autophagy. These downstream effects explain the broad metabolic phenotype observed in MOTS-c-treated animals and provide the rationale for its research in metabolic disease, exercise physiology, and aging.

Nuclear Translocation — A Unique Property

Under cellular stress conditions — including oxidative stress, heat shock, and metabolic challenge — MOTS-c translocates from the cytoplasm to the nucleus. Once nuclear, MOTS-c acts as a transcriptional regulator, binding to specific promoter elements and modulating expression of stress response genes. This dual cytoplasmic/nuclear function is unusual among peptides and positions MOTS-c as a direct link between mitochondrial stress sensing and nuclear gene regulation.

Metabolic Research Findings

Insulin Sensitivity and Glucose Metabolism

The foundational MOTS-c paper (Lee et al., 2015, *Cell Metabolism*) demonstrated that intraperitoneal MOTS-c administration in diet-induced obese mice significantly improved insulin tolerance (ITT) and glucose tolerance (GTT) compared to vehicle-treated controls. Skeletal muscle glucose uptake was markedly enhanced. Importantly, this effect was independent of body weight changes over short treatment periods, suggesting direct metabolic action rather than calorie-expenditure effects.

Subsequent work has confirmed and extended these findings. In models of high-fat diet-induced insulin resistance, MOTS-c prevents the development of insulin resistance when administered prophylactically, and partially reverses it when administered therapeutically. AMPK pathway activation in skeletal muscle appears central to these effects.

Obesity and Fat Mass

Chronic MOTS-c treatment in rodents on high-fat diet reduces fat mass accumulation, particularly in visceral adipose depots, without significant reduction in lean mass. The proposed mechanisms include increased fatty acid oxidation in adipocytes and skeletal muscle, reduced adipogenesis, and enhanced thermogenesis via brown adipose tissue activation. These effects position MOTS-c as a potential research tool in obesity biology.

Exercise and Physical Performance Research

A 2021 paper by Reynolds et al. in *Nature Communications* identified MOTS-c as an exercise-responsive hormone. In both rodents and humans, plasma MOTS-c levels increase with acute exercise and chronic training. When exogenous MOTS-c was administered to sedentary old mice, treadmill capacity, grip strength, and metabolic efficiency improved in ways that paralleled exercise training adaptations. The authors proposed MOTS-c as a potential "exercise mimetic" — a compound that partially replicates the molecular signals of physical activity at the cellular level.

MOTS-c levels also vary with age and genetics. Studies of centenarian populations have identified a specific MOTS-c variant (K14Q) enriched in long-lived Japanese men that improves upon wildtype MOTS-c activity in model systems. Plasma MOTS-c levels decline with age in both humans and rodents, mirroring the age-associated metabolic decline and reduced exercise capacity that characterize normal aging.

Aging and Longevity Research

MOTS-c's role in aging biology has drawn increasing research attention since 2018. In naturally aged mice (20–24 months), MOTS-c administration improved physical function, reduced systemic inflammation (as measured by cytokine profiles), and extended median survival in some experimental cohorts. These findings are consistent with MOTS-c's position as an AMPK activator — AMPK signaling is well-established as a pro-longevity pathway, activated by caloric restriction and exercise, and associated with extended healthspan across multiple model organisms.

The evolutionary logic of MOTS-c as an aging signal is compelling: mitochondria are both the primary site of cellular energy production and a major source of reactive oxygen species. A mitochondrially-encoded peptide that activates metabolic adaptation and stress resistance pathways represents an elegant feedback mechanism — cells signal nuclear and systemic programs for metabolic adjustment directly from the organelle most sensitive to metabolic conditions.

Human Research Context

Direct human research on exogenous MOTS-c administration is limited as of 2026. The bulk of evidence is from rodent models. However, correlative human studies have confirmed that: (1) plasma MOTS-c is measurable in humans, (2) levels are exercise-responsive, (3) levels decline with age, and (4) specific genetic variants in the MOTS-c coding region associate with longevity phenotypes in human population studies (particularly in Japanese and Ashkenazi Jewish cohorts). Interventional human trials with exogenous MOTS-c had not been published as of this writing.

Administration and Stability Considerations

MOTS-c research protocols in animals have used intraperitoneal and subcutaneous routes at doses of 5–15 mg/kg. The peptide is relatively small and hydrophilic, with reasonable reconstitution stability in aqueous solutions. As with most research peptides, storage as lyophilized powder at −20°C is standard, with reconstituted solutions used within 4–8 weeks under refrigeration. No significant immunogenicity has been reported in repeat-dosing rodent studies.

Research Use Only — Disclaimer. This document is prepared for laboratory and research reference purposes only. MOTS-c is not approved by the FDA for human therapeutic use. All evidence cited pertains to preclinical research models and observational human studies. This content does not constitute medical advice. Researchers must comply with applicable institutional and jurisdictional regulations.

References

1. Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." *Cell Metab*. 2015;21(3):443–454.
2. Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." *Nat Commun*. 2021;12:470.
3. Zempo H, et al. "A mitochondria-derived peptide, MOTS-c, regulates skeletal muscle differentiation." *Biochem Biophys Res Commun*. 2021;546:165–170.
4. Lu H, et al. "MOTS-c: A promising mitochondria-derived peptide for therapeutic exploitation." *Front Endocrinol*. 2023;14:1160534.
5. Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ." *Proc Natl Acad Sci USA*. 2001;98(11):6336–6341. [Humanin, related MDP]
6. Kim KH, et al. "A mitochondria-derived peptide, humanin, and its pathological roles." *Mol Cells*. 2017;40(10):721–727.